<DOC>
	<DOCNO>NCT00226187</DOCNO>
	<brief_summary>A randomized , double-blind trial docosahexaenoic arachidonic acid supplementation breast-fed preterm infant Background : Docosahexaenoic acid ( DHA ) arachidonic acid ( AA ) essential preterm infant . Human milk preterm formula contain DHA AA , low concentration require approximate utero accretion rate . Objective : To evaluate effect high dose DHA AA supplement breast-fed preterm infant early neonatal period . Primary endpoint neurodevelopment 6 20 month age . Design : A randomized double-blind placebo-controlled study carry four Norwegian neonatal center . Subjects method : Infants birth weight &lt; 1.5 kg randomize either intervention control group . All infant receive fortify human milk , daily dose 0.5 ml study oil per 100 ml milk . Infants intervention group receive oil DHA AA ( Formulaid , Martek , USA ) , control oil contains vegetable oil without DHA AA . Blood sample collect birth ( cord ) , start stop intervention . Plasma analyze fatty acid pattern use high performance liquid chromatography .</brief_summary>
	<brief_title>A Randomized Clinical Trial Supplementation DHA AA Preterm Infants</brief_title>
	<detailed_description />
	<mesh_term>Birth Weight</mesh_term>
	<criteria>Birth weight &lt; 1500 g Born one 4 participate neonatal center Norway Cerebral haemorrhage ( stage 3 4 ) Major congenital malformation suppose affect growth development Illness require prolong parenteral nutrition ( &gt; 4 week )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Month</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Fatty acid</keyword>
	<keyword>Human milk</keyword>
	<keyword>Infant development</keyword>
	<keyword>Very low birthweight infant</keyword>
</DOC>